Valvular Heart Disease (ABIM Review)

Imagine you are staring at an echocardiogram report for a 75 year old patient admitted with heart failure. Right. The ejection fraction is 35%. The aortic valve area is 0.8 centimeter squared. And you know, by all definitions that is severe stenosis. Absolutely. But then you look at the mean transvalvular gradient and it is only 25 millimeters of mercury. So is this a surgical emergency requiring a new valve right now? Or is this just a failing left ventricle struggling against a mildly stiff valve? Oh, man. That right there is the absolute definition of diagnostic muddy waters. Yeah. And it is exactly the kind of, you know, high stakes gray area clinical scenario that keeps you awake at night when you're covering the cardiac care unit. It really does. Well, welcome to the ABM series here on evidence at the bedside. I am Dr. Taylor. And I am Dr. Griffin. Our mission for this installment of the Ebene series is to unpack the recent guidelines on valve-ylar heart disease. And we are not just going to recite criteria. No, definitely not. We are going to master the underlying diagnostic reasoning, untangle the complex management algorithms and really highlight the classic board traps standing between you and your ABM certification. Exactly. And to do that, before we even look at a complex TE report or argue over stroke volume indices, we have to start where the boards always start right at the bedside with the stethoscope. Because the literature is incredibly clear that valve-ylar lesions progress very insidiously. Yeah, they really sneak up on you. Did you? Patients unconsciously limit their activity over years. Like they stop walking at the hill, they take the elevator instead of the stairs. Right, they just adapt. Exactly. So by the time they actually sit in your clinic and complain of exertional dysmia, the compensatory mechanisms of the heart are usually completely exhausted. Which brings us to the foundational framework you need to use to categorize that progression. It's the American College of Cardiology and American Heart Association staging system for valve-ylar heart disease. It is a fourth stage system and you really need to understand the pathophysiology behind the transitions. Yeah, the boards love testing the transitions. They do. So stage A is at risk. These are patients with the substrate for disease, but no actual valve dysfunction yet. So like, think of a patient with a bicuspid aortic valve that still opens and closes perfectly. Right. Or someone with a history of rheumatic fever whose leaflets haven't scarred down yet. Exactly. Then you move to stage B, which is progressive. Here we have mild to moderate disease. The valve is starting to calcify or leak, but the patient is completely asymptomatic. Right. Because the left ventricle is successfully handling the load. It's either undergoing compensatory hypertrophy or dilation. Yeah, it's coping. But then, and this is where you have to pay attention, we cross the critical threshold into stage C, which is asymptomatic severe. And the guidelines intentionally split this into C1 and C2. They do. And understanding the difference is absolutely paramount for the boards. All right. Because stage C1 means you have severe valve-ylar disease, but the ventricle is still holding on. It's still compensated. Exactly. The ejection fraction is still normal. But stage C2, that is the panic zone. Total panic zone. This is asymptomatic severe disease, but with decompensation of the ventricle, the heart muscle itself is failing. The EF is dropping. Right. So even if the patient sits in your clinic and swears they feel fine, you know their myocardium is waving a white flag. And finally stage D is symptomatic severe. Severe disease and the patient feels it. Understanding those transitions dictates your surgical triggers. But let's bring it back to the physical exam for a second. Oh, the classic board track. Right. Because the test riders love to exploit the disconnect between hemodynamics and what you actually hear in your stethoscope. Yeah, especially with aortic stenosis. The classic textbook teaching is that late peaking, systolic, crescendo, decrescendo murmur at the right upper sternal border. Radiating to the carotids. Exactly. Accompanied by a delayed, weak carotid upstroke pulsus tardis, aparvus. And for mitral regurgitation, you know, you are listening for that hollow systolic murmur at the apex radiating to the axilla, completely obliterating the first heart sound. Right. But there is a massive physical exam pitfall here, especially with aortic stenosis. There really is. The volume or the harshness of an AS murmur does not correlate with its severity. Not at all. And you have to think about the actual physics of a murmur. Right. A murmur is just the sound of turbulent kinetic energy. So to generate a loud grade five harsh murmur, you need a really strong pump blasting blood at high velocity through a narrow opening. Exactly. But what happens when the pump fails? Right. In a patient with end stage, critically ordex stenosis and a failing left ventricle, they simply cannot generate enough forward flow. They just don't have the kinetic energy. Exactly. They cannot produce enough kinetic energy to create loud turbulence across that heavily calcified valve. And the boards will explicitly test this. Oh, absolutely. They will give you a patient in cardiogenic shock, gray modeled with a quiet grade one out of six murmur at the right upper sternal border. And they'll try to convince you the aortic valve cannot possibly be the primary issue because the murmur is so soft. Right. But you have to know that the absence of a loud murmur in the setting of heart failure is actually a massive red flag. Yeah, it's a terrifying finding. And another trap in that same vein is the difference between chronic and acute valvular regurgitation. Oh, this is a great one. Let's say you are covering the CCU, a patient is admitted with an inferior myocardial infarction, and suddenly their blood pressure tanks and they are drowning in flash pulmonary edema. Okay, so you suspect an acute papillary muscle rupture causing severe mitral regurgitation. So you put your stethoscope on the chest and you're expecting to hear a massive deafening hall of systolic murmur. Are you here almost nothing? Exactly. Maybe a tiny soft, early systolic squeak. I remember being an intern and being totally bewildered by this. It feels like the physical exam is lying to you. It really does. But if you look at the compliance curves, it makes perfect sense. Right. Because in chronic mitral regurgitation, the left atrium has years to stretch. It dilates and becomes highly compliant. Like a giant floppy balloon. It can absorb all that regurgent volume at a low pressure. Exactly. Which keeps the pressure gradient between the ventricle and the atrium wide throughout the entire duration of systole. And that wide, sustained gradient is what gives you a long, hollow, systolic murmur. But in an acute rupture, that left atrium is completely normal sized and stiff. It is not prepared for this volume. Right. So when the ventricle contracts, it blasts blood backward into an unyielding tight chamber. The pressure and the left atrium skyrockets instantly. Within milliseconds. Within milliseconds, the pressure and the left atrium equals the pressure and the left ventricle. And when pressure is equalized, flow stops. Exactly. And when flow stops, the murmur stops. It just pierce physics. And the exact same physiology applies to acute, severe, aortic regurgitation from infective endocarditis. Oh, totally. The left ventricle hasn't had time to undergo eccentric hypertrophy. So you won't see the classic, wide pulse pressure. You won't feel bounding water hammer pulses. Right. If you wait around looking for a massive dilated chamber or a classic textbook murmur in an acute regurgitant lesion, your patient will literally die. They will. Now, we always talk about these lesions and isolation, but I know you like to use an analogy to ground the hemodynamics for people. Yeah, I always think of valve lesions like house hardware, but you have to imagine it in a really extreme scenario. Okay, look at on me. So a stenotic aortic valve isn't just a stucdoor. It is a stucdoor in a burning building where the left ventricle is frantically trying to push everyone out. Wow. Okay, intense. Right. The pressure inside the room skyrockets, the walls of the ventricle get incredibly thick from the effort, which is concentric hypertrophy, but eventually the muscle just burns out and gives up. Right. Regurgitation, on the other hand, is a leaky hinge. The door swings open fine, but volume constantly spills backward, flooding the room and creating a massive volume overload problem. And that stretches the walls out until they thin and fail. Exactly. And when we talk about sending a surgeon in to fix those doors and hinges, we have to look at surgical risk. We do. And the guidelines heavily emphasize the use of risk calculators. Primarily, the Society of Thoracic Surgeons or SPS score. Right. And the SPS score is mathematically robust. It calculates risk based on age, renal function, severe lung disease, prior chest radiation. But it has a glaring blind spot. A huge one. It completely misses the eyeball test for frailty. Yes. The evidence explicitly notes this limitation. You can have an 82-year-old patient with great kidneys and lungs who scores a low risk on the SPS calculator. Right. But when you walk into the room, you know, they weigh 90 pounds. They can't rise from a chair without assistance. And their grip strength is non-existent. And you just know they're going to struggle. Because frailty is a distinct geriatric syndrome. It is a severe decline in physiologic reserve across multiple organ systems. If that frail patient undergoes a massive open-chest operation and gets placed on a cardiopulmonary bypass pump for three hours, their actual risk of mortality or failure to thrive is astronomical. Regardless of what the SPS calculator says. Exactly. And the boards will test this by asking you what the multidisciplinary heart team should consider beyond the standard risk scores. And the answer is a formal objective frailty assessment. Always. All right. So we've established the foundation. Now, we need to transition from the bedside directly into the most heavily tested specific valve lesion on the boards. Aortic stenosis. Aortic stenosis. We touched on the diagnostic criteria earlier, but let's really lock them in. Yeah, let's do it. To diagnose severe aortic stenosis on an echocardiogram, you need one of three findings. First, a valve area of less than or equal to 1.0 centimeter squared. Right. Second, a maximum jet velocity or Vmax of greater than or equal to 4.0 meters per second. Or third, a mean transovular gradient of greater than or equal to 40 millimeters of mercury. Which brings us right back to our opening hook. Oh, right. The patient with an EF of 35% a valve area of 0.8, but a mean gradient of only 25. Right. The area says severe, but the gradient says moderate. It's so confusing. It is. This is the classic low flow, low gradient aortic stenosis dilemma. The ventricle is weak. The forward flow is severely reduced, which is defined as a stroke volume index of less than or equal to 35 millimeters per meter squared. And because the flow is low, the gradient is low. Right. So the core clinical question here is really one of causality. Exactly. Is the valve area 0.8 because the valve is literally a calcified rock, structurally incapable of opening any further? Right. Or is the valve area 0.8 simply because the failing left ventricle is so weak, it can't generate enough force to push open a moderately stiff, but otherwise pliable valve. And that second scenario is what we call pseudostinosis. Right. The valve isn't the primary culprit. It's just a bystander to a failing pump. And figuring out which of those two realities you were dealing with is a highly testable concept. Yeah. You have to use a dobutamine stress echocardiogram at the bedside. Okay. Break that down for us. Confused dobutamine, which is a beta one agonist, to provide inotropic support. You're essentially whipping the tired left ventricle to see if it can still mount a response. You give the dobutamine and you watch the echo screen in real time. Exactly. You watch the stroke volume increase. Now you look at the valve. Right. If the stroke volume goes up and the valve area stretches open, say it increases from 0.8 to 1.3 centimeters squared while the gradient really changes, you have your answer. You've diagnosed pseudostinosis. You got it. The valve had the capacity to open all along. It just needed a stronger push. So the pathology is underlying heart failure, not a surgical valve. Exactly. You do not send this patient for a valve replacement. But let's look at the other outcome. You give the dobutamine the stroke volume increases, but the valve area stays rigidly, stubbornly fixed at 0.8 centimeter squared. It absolutely refuses to budge. Meanwhile, the mean gradient shoots up from 25 to 45 millimeters of mercury. Right. So in that case, you have just diagnosed true severe low-flow, low-gradient aortic stenosis. The valve is definitively the problem. Exactly. This patient needs a new aortic valve. But you know, the literature doesn't stop there. Of course not. There is a second, even more deceptive phenotype you have to watch out for on the exam. Paradoxical low-flow, low-gradient severe aortic stenosis. Oh, this one is tricky. It is. In this scenario, the valve area is small. The flow is low. The gradient is low. But the ejection fraction is completely normal. It is greater than or equal to 50 percent. Yeah. And this completely breaks the brains of a lot of residents. How does a heart with a normal percentage squeeze produce low-forward flow? Right. Because you have to decouple ejection fraction from stroke volume. Ejection fraction is just a ratio. It is literally just the percentage of blood in the ventricle that actually gets ejected. Exactly. It is really patient with decades of severe untreated hypertension. They have developed massive concentric left ventricular hypertrophy. The walls of the heart are incredibly thick, growing inward. Right. So the actual cavity inside the ventricle has shrunk to the size of a walnut. In diascal, that tiny county might only hold 50 milliliters of blood. Wow. So if the heart squeezes out 30 milliliters of that 50, the ejection fraction is 60 percent. Exactly. From paper, the squeeze looks perfectly normal. But a 30 milliliters stroke volume is terrible. It's a pathetic. There simply is not enough volume and therefore not enough kinetic energy to generate a high-pressure gradient across the aortic valve. Right. They have high systemic impedance, low cavity volume, a normal percentage squeeze, but pathetic forward flow. And because the EF is already normal, you can't really use Dubutamine to whip the heart, right? There isn't much reserve left to recruit. Exactly. The headlines recommend an alternative path. If you suspect paradoxical low flow, low gradient AS, you get a CT scan to measure the aortic valve calcium score. Okay. And what are the cutoffs there? A very high calcium burden. Usually over 2,000 Agustin units in men, or 1,200 in women, objectively confirms the valve is severely diseased. That is such a high yield pearl. Okay. And if you have a diagnosis and confirm severe aortic stenosis, you face the management algorithm. Right. And the decision basically boils down to traditional open-heart surgery, surgery aortic valve replacement, or S-A-V-R versus transcaffedery aortic valve implantation, or T-A-V-I. And the guidelines draw a very distinct age cutoffs based almost entirely on the concept of durability. Yes. And you absolutely must commit these age brackets to memory for the boards. T-A-V-I is the class one recommendation for older patients, right? Specifically those over the age of 80, or younger patients whose life expectancy is less than 10 years due to other severe comorbidities. Right. Because the transcatheter approach avoids the massive physiological insult of a sternotomy and cardiopulmonary bypass in an elderly frail population. Exactly. On the other side of the spectrum, traditional open-heart surgery, S-A-V-R, is recommended for patients younger than 65 years old, or those with a life expectancy greater than 20 years. Because we know surgical valves have a decades-long track record of proven durability. Right. T-A-V-I technology is miraculous, but we simply do not have 30 years of longitudinal data on these transcatheter valves yet. Yeah, you do not want to put a T-A-V-I in a 60-year-old, only for it to structurally degenerate 10 years later. Leaving them facing an incredibly complex, high-risk, valve-in-valve procedure, or a latent life-open surgery. Right. And for the patients caught in the middle, ages 65 to 80, it becomes a nuanced, shared decision-making process. Exactly. Now, before we move off aortic stenosis, we have to address one of the most classic board distractors of all time. Oh, I know exactly what you're going to say. Right. We know that the pathophysiology of calcific aortic stenosis involves inflammation, lipid deposition, and the transdifferentiation of valve interstitial cells into osteoblast-like cells. Under a microscope, it looks remarkably similar to vascular atherosclerosis. So naturally, the medical community asked, "If it looks like atherosclerosis, why don't we treat it like atherosclerosis?" Let's give them a statin to halt the progression. It sounds so incredibly logical, which is why the boards love it. But the trial data completely annihilated that hypothesis. Absolutely crushed it. So have randomized trials prove that statins do absolutely nothing to slow, stop, or reverse the progression of calcific aortic stenosis? Right. So if you see a board question offering a high-intensity statin to delay the need for valve replacement, cross it out immediately. Do not fall for it. The only reason a patient with aortic stenosis should be on a statin is if they have a separate, primary, or secondary indication for cardiovascular risk reduction. Exactly. Okay. So we've explored the stuctor of the left ventricle. Now let's examine the leaky hinge aortic regurgitation. When we trace the etiology of aortic regurgitation, it invariably forces us to look at the developmental anatomy of the valve. Specifically, the bicuspid aortic valve. Right. The hemodynamics of chronic aortic regurgitation are fascinating because they represent the ultimate volume overload state. Yeah, the left ventricle is pumping a massive stroke volume forward into the high-pressure aorta. The diastole, a significant portion of that blood, just falls backward through the incompetent valve right back into the ventricle. So to manage this relentless dual-filling blood coming from the left atrium normally, plus blood dumping backward from the aorta, the ventricle undergoes eccentric hypertrophy. It adds circummiers and series. It dilates massively. And the left ventricle can adapt like this for years, becoming absolutely enormous to accommodate the stroke volume while keeping filling pressures relatively low. But this adaptation has an expiration date. It definitely does. Eventually, the extreme dilation increases wall stress to the point where intrinsic contractility begins to fail. And the boards will aggressively test your knowledge of exactly when to intervene in an asymptomatic patient before that failure becomes irreversible. Right. For asymptomatic severe aortic regurgitation, the surgical triggers are incredibly specific. If you intervene, if the left ventricular ejection fraction drops to less than or equal to 55%, or if the left ventricular and systolic dimension, the LVE SD stretches beyond 50 millimeters. Wait, I want to pause on that 55% ejection fraction cutoff. Yeah, it's a weird number. Because in almost any other clinical context, an EF of 54% is considered entirely normal. Right. But in severe aortic regurgitation, 55% is a terrifying cliff. Why is that? Because the left ventricle is massively dilated and the preload is astronomical. Based on the Frank Starling mechanism, that heart should be contracting with super normal vigor. Right. The EF should easily be 65 or 70%. Exactly. If a heart with that much stretch and volume drops to an EF of 55%, the myocardium is fundamentally failing. - You must get them to the operating room before severe myocardial fibrosis sets in. - Absolutely. And when we look for the cause of this regurgitation, especially in younger patients, we frequently find a bicuspid aortic valve, which affects roughly one to two percent of the population. - Right. And usually the abnormal shear stress across the two fused leaflets causes early calcification, leading to aortic stenosis in a patient's 50s or 60s. - But in a distinct minority, it presents as pure aortic regurgitation. - And the absolute must-know board pearl here is that a bicuspid aortic valve is not just an isolated structural valve defect. - No, it is a heritable aotopathy. - Exactly. Embryologically, the neural crest cells that migrate to form the aortic valve are the exact same cells that form the media of the ascending aorta. - Right. If the valve is structurally abnormal, you have to assume the cellular architecture of the aortic wall is also compromised. - And if you identify a bicuspid aortic valve in a patient, the guidelines mandate that you must screen their first-degree relatives with an echocardiogram. - But more importantly, for the patient right in front of you, you have to meticulously monitor the size of their ascending aorta. - Right, because that weakened wall is subjected to abnormal, turbulent shear stress every single time the heart beats. - It is a massive setup for aneurysm and a section. - And the surgical cutoffs for retiring the dilated ascending aorta in a bicuspid patient are tiered and highly testable. - Okay, let's break them down. - The baseline rule is that surgical repair of the ascending aorta is indicated when the diameter reaches 5.5 centimeters. - Right, but that threshold drops. - It does. It drops to 5.0 centimeters if the patient has additional high-risk features like a family history of aortic dissection or if serial imaging shows the aneurysms expanding rapidly, which is defined as growing more than 0.5 centimeters in a single year. - And crucially, the threshold drops even further to 4.5 centimeters if the patient is already scheduled to go into the operating room to have their bicuspid bowel for place. - Right, it is just a matter of surgical economy. - If the chest is already open, the patient is on cardiopulmonary bypass and the aorta is 4.6 centimeters, you replace the ascending aorta right then and there. You do not leave a dilated disease day order behind only to subject the patient to a second massive high-risk open-heart surgery a few years later. - That makes perfect sense. Now, there is one more classic trap here. - Okay, what is it? - The examiners will offer you an asymptomatic patient with severe aortic regurgitation and ask how to manage them medically to delay the need for surgery. - Yes, and they will offer options like ACE inhibitors, ARBs, or dihydropyridine calcium channel blockers to reduce after-load. - Exactly, do not fall for it. - Right, you cannot medicate away a massive structural leak. - The evidence clearly demonstrates that vasodilator therapy in isolated aortic regurgitation does not delay the need for surgical intervention. - The only time the guidelines support using these medications in an AR patient is if they have a separate diagnosis of systemic hypertension. - Right, you treat the blood pressure to prevent further cardiovascular damage, but you are not fixing the leaky hinge. - Exactly. So we've covered the aortic comprehensively. Now let's follow the blood backward into the left atrium. - This brings us face to face with the mitral valve. - Right, and while degenerative disease and calcification rule the left ventricles exit door, the entrance door, the mitral valve, is haunted by a different ghost entirely. - Mitral stenosis is dictated almost exclusively by rheumatic heart disease. - And the legacy rheumatic fever is profound. The inflammatory process causes the commissioners of the mitral valve to fuse together. - Creating this thick, domed hockey stick or fishmouth deformity you see on an echocardiogram. - Right, blood returning from the lungs into the left atrium hits a brick wall trying to get into the left ventricle. - Because the left atrium cannot empty properly, the pressure builds and backs up directly into the pulmonary veins. - Which drives the classic symptoms. Patients develop profound exertional dysmia. - And the chronic high pressure in the pulmonary capillaries can cause them to rupture into the alveoli leading to hemoptysis. - Right, and over time this unrelenting pulmonary hypertension forces the right ventricle to fail, leading to lower extremity, edema, acytes, and hepatic congestion. - And at the bedside, the ascultatory findings are incredibly distinct. - Oh yeah, you will feel a tapping left ventricular impulse. - The first heart sound S1 is shockingly loud because the thickened stiff mitral leaflets are slammed shut by the full force of ventricular cystal. And you will hear a sharp diastolic opening snap followed by a low-pitched rumbling diastolic number at the apex. - And here's a high-yield clinical pearl. The closer that opening snap occurs to the S2, the more severe the stenosis. - That timing is crucial. - Right. If the opening snap happens almost immediately after the aortic valve closes, it means the pressure inside the left atrium is incredibly high. - So high that it forces the fused mitral valve open the millisecond? The left ventricular pressure starts to drop. - Exactly. Now, when it comes to fixing this, the premier intervention for symptomatic severe rheumatic mitral stenosis isn't always open heart surgery. - No, it is a percutaneous balloon, mitral commissarotomy, or PBMC. - Right. Interventionalists, theoretic catheter across the atrial septum, position of specialized balloon directly inside the stenotic mitral valve and rapidly inflate it to physically tear apart those fused comichers. But, you know, I'm looking at the anatomy of rheumatic mitral stenosis. And the idea of inflating a high pressure balloon in there terrifies me. - Why is that? - We are talking about a massive dilated left atrium that is practically a stagnant pond. If there's a clot hiding in the left atrial appendage, aren't we just gonna blast it straight to the brain? The second we manipulate that balloon. - And that terror is exactly what the boards will test. You have to know the absolute contraindications to a balloon commissarotomy. - Okay, listen up. - First and foremost, as you just pointed out, you must perform a TEE, a transisophageal echocardiogram immediately before the procedure to rule out a left atrial thrombus. - Right. If there is a clot, PBMC is absolutely contraindicated. - Second, you cannot perform this procedure if the patient has concurrent, moderate to severe mitral regurgitation. - Because the balloon works by violently tearing the tissue at the comichers. - Exactly. If the valve is already leaking significantly, tearing it further will make the regurgitation catastrophically worse, potentially throwing the patient into acute cardiogenic shock. - That makes total sense. And the third contraindication. - If the echocardiogram shows the valve is severely densely calcified and non-pliable. - Because the balloon won't tear the comichers neatly, it will just rupture the body of the leaflet itself. - Right. In any of those three scenarios, clot, severe regurgitation or heavy calcification, the balloon is out. The patient requires a surgical, mitral valve replacement. - Okay, now we must discuss what is arguably the most dangerous, non-negotiable board trap in this entire topic. - Let's hear it. - It is the intersection of mitral stenosis and atrial fibrillation. - Oh, this is massive. - As the left atrium in mitral stenosis dilates, the tissue stretches, scars and becomes inflamed. It is the perfect electrophysiological breeding ground for atrial fibrillation. - And nearly 50% of these patients will eventually develop it. - Exactly. Now, if you are presented with a patient who has mitral stenosis and atrial fibrillation, I need you to mentally erase everything you know about standard non-vavular atrial fibrillation management. - Right. Do not calculate a CHA2DS2VAC score. It is completely utterly irrelevant. - It does not matter if their score is a zero. It does not matter if they are a healthy 25 year old with zero comorbidities who runs marathons. And whatever you do, do not prescribe a direct oral anti-coagulant, a DOAC like River Roxaban or a Pixaban. - The evidence here is absolutely definitive. The Invictus trial looks specifically at patients with rheumatic heart disease and atrial fibrillation. - The researchers hope they could use DOACs to free these patients from the burden of INR monitoring. - But the trial showed a significantly higher risk of ischemic stroke and death in the patients taking River Roxaban compared to those taking traditional warfern. - And the underlying mechanism explains why DOACs fail here. In standard non-valvular atrial fibrillation, thrombi almost exclusively form in the left atrial appendage. - But in a rheumatic mitral stenosis, the entire body of the massive dilated left atrium is a low flow stagnant swamp. - The endocardial endothelium is severely diseased. The thrombotic risk is systemic throughout the chamber and it is astronomical. - Right. The targeted mechanism of a DOAC simply isn't robust enough to overcome that level of thrombogenicity. - Therefore, the absolute must know pearl. Mithral stenosis plus atrial fibrillation equals a vitamin K antagonist. - Warfern only. - And you target an INR of 2.0 to 3.0. - They will try to trick you with a patient who hates getting their blood drawn and begs for a DOAC. You have to hold the line. The answer is always warfern. - Always. Okay, so if mitral stenosis is a mechanical plumbing issue of a fused valve, mitral regurgitation forces us into a completely different diagnostic headspace. - Right. When a mitral valve leaks, we have to determine whether we are dealing with a broken valve which we call primary MR or a broken ventricle which we call secondary MR. - And that distinction changes the entire trajectory of the patient's care. - It really does. Let's start with primary MR. - Okay. In primary mitral regurgitation, the physical components of the valve, the leaflets or the corn. - The most common cause in developed nations is miximatus degeneration leading to mitral valve prolapse. - You might encounter Barlow syndrome, which involves redundant billowing leaflets. - Or fibroelastic deficiency, where a weakened cord spontaneously snaps. - Creating a flail leaflet that whips back into the atrium during systole. - The valve itself is the disease. - Right. But secondary mitral regurgitation is a disease of ventricular geometry. - If you were to take the valve out and examine it on a surgical table, it would look structurally perfect. - The problem is the left ventricle below it. - Exactly. Imagine a patient who suffers a massive anterior myocardial infarction. Or someone with a severe non-eschemic dilated cardiomyopathy. - As the ventricle balloons outward, it literally drags the papillary muscles down and away from the mitral anulus. - This creates severe tethering. The leaflets are stretched so tightly by the displaced papillary muscles that they simply cannot reach each other to close during systole. - The valve is just an innocent bystander being pulled apart by a failing ventricle. - And because the pathophysiology is so different, the management algorithms are entirely divergent. - Let's like a primary MR first. For a structurally broken valve, surgery is the definitive curative treatment. - Obviously, if the patient is symptomatic, you operate. - But the boards will test your timing on the asymptomatic patient. - The primary MR, you send an asymptomatic patient to the operating room. If their ejection fraction drops to less than or equal to 60%. - Or are, if their left ventricular insustolic dimension reaches 40 millimeters or more. - And that ejection fraction cutoff of 60% is one of the most vital hemodynamic concepts you can learn. - The rule here is that 60 is the new 50. - Exactly. In a normal heart, we don't usually panic until the EF drops to 50 or 55%. But think about the physics of severe mitral regurgitation. - When the left ventricle contracts, the blood has two potential escape routes. - Right. You can go forward out the aortic valve, which requires pushing against the high impedance of systemic blood pressure, say 120 millimeters of mercury. - Or it can just blast backward through the incompetent mitral valve into the left atrium, which has a pressure of maybe 15 millimeters of mercury. - It's going to take the path of least resistance. - Of course. The ventricle rapidly unloads a massive amount of volume backward into this low pressure sink. - Because the aortic valve is artificially eliminated, the ejection fraction should look spectacular. It should be 70 or 75%. - Right. So if you evaluate a patient with severe primary mitral regurgitation and their ejection fraction is 55%, they might look fine on paper. - But they're actually in stealth, severe heart failure. - Their intrinsic myocardial contractility is severely depressed. It's just being masked by the low afterload. - If you send that patient to the OR, fix the valve and suddenly force that we can ventricle to pump every drop of blood forward against high systemic pressure. - The heart will fail in the post-op recovery room. - You must intervene before the EF drops below 60%. - And when you do intervene for primary MR, the guidelines are in the fatigue. Surgical repair of the patient's native valve is wildly preferred over replacing it with a prosthetic. - Yes. Repairing the valve, preserves the sub-valvular apparatus, the complex web of cordy-tendony that connects the leaflets to the papillary muscles. - Preserving those cords maintains the illiptical geometry and the contractility of the left ventricle. - Now, contrast all of that with secondary MR. - Right. Totally different beast. - In secondary MR, if you take a patient with a massive, diluted cardiomyopathy to the operating room and subject them to the trauma of a sternotomy, just to sow in a new mitral valve, you haven't actually fixed the primary problem. - The ventricle is still severely diseased and failing. - The data clearly shows that surgical valve replacement in this context rarely improves long-term mortality. - So the first line treatment for secondary MR isn't a scalpel. It's aggressive, guideline directed medical therapy, or GDMT. - You must relentlessly uptry to treat their beta blockers, ACE inhibitors, or ARNIs, mineral-locoriticoid receptor antagonists, and SGLT2 inhibitors to induce reverse remodeling of the ventricle. - You also deploy cardiac resynchronization therapy, or CRT, if they meet the criteria for a bi-ventricular pacemaker. - If you shrink the ventricle, the papillary muscles move back into position and the regurgitation often resolves. - But, you know, we all have patients who remain severely symptomatic despite absolute maximum medical and electrical therapy. - Right. They're constantly being admitted for volume overload. - And this is where interventional cardiology has fundamentally changed the landscape. - For highly selected patients with secondary MR, specifically those with an ejection fraction between 20 and 50% who are still symptomatic, despite max GDMT. - The guideline support using transcafeter edge-to-edge repair, commonly known as TEER, or the metric lip. - It's an elegant procedure. You go in percutaneously through the femoral vein, cross the atrial septum, grasp the anterior, posterior leaflets of the mitral valve, and clip them together right in the middle. - This creates a double orifice valve, like a figure eight. - It significantly reduces the regurgent volume, and has been shown to reduce hospitalizations and improve survival in these highly refractory heart failure patients. - But remember the hierarchy for the boards. TEER in secondary MR is strictly a downstream option, only the correct answer after all medical therapies have been exhausted. - Absolutely. Yeah. Okay. So we spent a lot of time on the left side of the heart, but to complete our hemodynamic picture, we have to look at the right side, specifically trocuspid disease. - Then we will tackle the intricate rules surrounding prosthetic valves and endocarditis. - Right. The tricuspid valve is often dismissed as the forgotten valve, but ignoring it on the boards is a guaranteed way to lose points. - Tri-cuspid regurgitation is almost always secondary, meaning it is functional. The leaflets are usually fine. - The most common driver is less sighted heart failure. High pressure in the left heart backs up into the lungs, causing pulmonary hypertension. - The thin walled right ventricle has to pump against this high pressure, so it dilates. - As it balloons outward, it pulls the tricuspid annualis apart, preventing the leaflets from co-apting. - We also see secondary TR caused by the very devices we use to treat heart disease. - Like pacemaker or defibrillator leads. They have to traverse the tricuspid valve to anchor in the right ventricle. - And sometimes those leads physically impinge on a leaflet, pinning it down so it can't close properly. - Now, the physical exam for severe TR is unforgettable. - When you look at the patient's neck, you will see giant CV waves in the jugular venous pulse. - Because the tricuspid valve is wide open, every time the right ventricle contracts, a massive pressure wave shoots straight backward up the superior venicava and into the jugular veins. - If you palpate their abdomen, you will feel a large pulse at all liver expanding with every cystal. - Medical management relies heavily on loop diuretics and aldosterone antagonists to relieve that profound venous congestion. - But you are walking a physiologic tightrope here. - You really are. The right ventricle is highly sensitive to preload. It relies on volume to maintain forward flow into the pulmonary bed. - If you aggressively overdiereese a patient with severe tricuspid regurgitation in an attempt to fix their edema, you will obliterate their right ventricular preload. - The cardiac output will crash and they will rapidly spiral into a acute renal failure and shock. - Right. When it comes to surgical intervention, the guidelines take a pragmatic approach. - If a patient with severe tricuspid regurgitation is already scheduled to undergo left-sided valve surgery, for instance, a mitral valve repair, the guidelines strongly recommend repairing the tricuspid valve at the same time. - Often by placing an anuloplast you ring to cinch the dilated anulus back together. - Now, let's synthesize all of this into the final pathway for many of these patients. Prostetic valves. - When a native valve is beyond repair, the heart team must choose between implanting a mechanical valve made of pyrolytic carbon or a bioprostetic valve, usually fashioned from porcine or bovine paracardial tissue. - And the decision requires balancing age, durability and the lifelong burden of anticoagulation. - The age parameters are strict. A mechanical valve is generally recommended for patients younger than 50 years old. - These valves are practically indestructible. They will easily last the patient's entire life. - But the tradeoff is severe. They are highly thrombogenic and require intense lifelong anticoagulation. - A bioprostetic tissue valve is recommended for patients older than 65 years. They do not require lifelong warfarin, but they are subject to structural valve deterioration. - Right. - A tissue roll might only last 10 to 15 years before it calcifies and fails. - For the patients caught between 50 and 65, it is a shared decision-making process. You have to weigh their bleeding risk, their lifestyle, and how willing they are to face a high-risk re-operation if a tissue valve degrades. - But the absolute must-know board pearls revolve around how we manage these valves once they are in the patient's chest, specifically the anticoagulation rules. - Let's make this unequivocally clear. - The patient has a mechanical heart valve. They strictly require a vitamin K antagonist, warfarin. - Under absolutely no circumstances, should you ever prescribe a DRAC for a mechanical heart valve? - The randomized trials attempted to use DOA season this population had to be stopped prematurely because the patients were suffering unexceptively high rates of catastrophic valve thrombosis and massive strokes. - Once you prescribe the warfarin, you must memorize the exact target INR goals. - They are heavily tested because they change based on the position of the valve and the patient's physiology. - Right, if a patient has a modern mechanical valve in the aorticulture, position and they have absolutely no other risk factors for clotting, the target INR is 2.5. But that target INR increases to 3.0 and 3 highly specific scenarios. First, if the mechanical valve is in the mitral position. Why? Because the flow of blood across the mitral valve is much slower under lower pressure and covers a larger surface area than the high velocity flow across the aortic valve. Slower flow equal stasis and stasis equal thrombosis. Exactly. The second scenario requiring an INR of 3.0 is if the mechanical valve is in the aortic position. But the patient has additional venous thromboembolism risk factors. This includes concurrent atrial fibrillation, severe left ventricular dysfunction, or a prior history of thromboembolic events. And the third scenario is historical but still tested. If the patient has an older generation, ball-in-cage mechanical valve, regardless of its position. The target is 3.0 because those designs are inherently more thrombogenic than modern biliflit valves. Furthermore, the guidelines mandate that low dose aspirin, usually 75 to 100 milligrams, should be added to the war-friend regimen for all patients with mechanical valves, provided their bleeding risk is acceptably low. This dual pathway targeting both the coagulation cascade and platelet aggregation, provides superior protection against valve thrombosis. All right, to close out our clinical discussion, I want to set up the final classic board trap. Okay, lay it on me. It concerns effective endocarditis proflaxis. Here is the scenario. You are seeing a 55-year-old patient in the clinic. They have a known by Cuspid aortic valve, but it functions perfectly. Okay. They are scheduled to get a routine screening colonoscopy next week. They read online that heart valves can get infected, so they ask you for a prescription for a moxacillin before the procedure. What do you tell them? You give them a hard, unequivocal, unapologetic no. This is one of the most frequently misunderstood and incorrectly practiced areas in daily medicine, and the boards will test it relentlessly. The guidelines for effective endocarditis prophylaxis underwent a massive paradigm shift over the last two decades. We used to hand out antibiotics like candy to almost anyone with a murmur for almost any invasive procedure. But the evidence caught up with the practice. The literature demonstrated two critical facts. First, the risk of inducing fatal anaphylaxis or driving widespread antibiotic resistance was vastly outweighing the theoretical benefit of preventing endocarditis. And second and more importantly, the bacteremia caused by everyday activities like chewing food or brushing your teeth exposes the heart to far more bacteria cumulatively than a single isolated endoscopic or dental procedure. So the current guidelines strictly limit prophylaxis to only the absolute highest risk patients. You must memorize this list. It is very short. Who gets prophylaxis? Patients with prosthetic heart valves, including both surgical and trans catheter valves. Patients with any prior history of effective endocarditis. Patients with unrepaired, cyanotic, congenital heart disease. And finally, cardiac transplant recipients who develop a structural valveulopathy. That is the entire list. A native bicuspiddeortic valve, mitral valve prolapse or mildly orthostanosis, do not qualify. And the restrictions don't just apply to the patients. They apply to the procedures. Right. Prophylaxis is only indicated for dental procedures that involve the active manipulation of gingival tissue, the pariapical region of the teeth, or outright preparation of the oral mucosa. Routine gastrointestinal or genoternary procedures like a screening colonoscopy and EGD or a cystoscopy do not require prophylaxis anymore. Period. Even if the patient has a mechanical valve, they do not get a moxacillin for a colonoscopy unless there is an active known infection in the GI or GU track that requires treatment anyway. If the patient does meet both strict criteria, for example, a patient with a mechanical mitral valve going in for a complex tooth extraction, the standard first line prophylaxis regimen is a moxacillin, two grams orally, taken 30 to 60 minutes before the procedure. If they have a documented penicillin allergy, the alternatives are syphlexin, azithromycin, or doxycycline. But the crux of the board question is always knowing exactly who to say no to. We have covered an immense amount of physiologic ground today. Let's rapidly summarize the absolute must-know takeaways for the A-bim exam. First, understand the hemodynamics of low flow, low gradient aortic stenosis. Know that you use a w-damine echo to differentiate pseudostinosis, where the valve opens from true severe stenosis, where the gradient spikes, but the valve stays locked. Second, cement the mitral stenosis anti-coagulation rule in your mind forever. Mitral stenosis plus atrial fibrillation strictly requires warfrinn because the entire left atrium is a thrombogenic swamp. The CHH-A2DS2VAC scores is not apply and DOACs like River Oxaban are explicitly contraindicated based on the Invictus trial data. Third, remember the paradox of primary mitral regurgitation. 60 is the new 50. The low after-load masks ventricular failure. You must send them for surgical repair before the ejection fraction drops below 60%. And finally, be incredibly stingy with infective endocarditis-proful axis. Limited strictly to the highest risk, valve prosthetics, and prior endocarditis. And only for invasive dental procedures, not routine GI or GU scopes. We want to thank you all for joining us on this rigorous exploration of the evidence. We hope dissecting the pathophysiology empowers your diagnostic reasoning, both when you are rounding on the wards and when you are sitting for the boards. Please take a moment right now to like, share, and subscribe to evidence at the bedside so we can keep bringing you these high-yield discussions. And as we sign off, I want to leave you with a provocative thought to mull over. With TAV, I continue to expand its indications into younger, lower-risk patient populations, and with transcaffeter edge-to-edge repair devices, pushing aggressively into both the mitral antricuspid spaces. Are we rapidly approaching an era where open heart valsertary becomes nothing more than a purely historical footnote? Or will the long-term realities? The unanswered question is about 20-year device durability, the persistent challenges of paravaluular leaks, and the complications of prominent pacemaker dependency, eventually bring the scalpel back into Vogue two decades from now. Keep that tension in mind the next time you're evaluating a patient in the CCU.